Equities research analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for United Therapeutics in a ...
A biotechnology company in Research Triangle Park has taken a major step to develop a new option for patients in need of a ...
We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...
The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a ...
It is hard to get excited after looking at United Therapeutics' (NASDAQ:UTHR) recent performance, when its stock has declined 7.4% over the past three months. However, a closer look at its sound ...
UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...
United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...
United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...
Two biotechnology companies, United Therapeutics Corp. and eGenesis, have been cleared to begin their studies this year.
On Friday, doctors at Massachusetts General Hospital announced that a 66-year-old New Hampshire man had successfully received ...
1d
Zacks.com on MSNStrength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength?United Therapeutics (UTHR) shares soared 4.9% in the last trading session to close at $370.74. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results